logo-loader
SELLAS Life Sciences Group Inc

SELLAS Life Sciences shares surge on Phase 2b results of breast cancer treatment

The company will talk with US regulators in December on the best way forward for the drug

cancer cell
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares climbed on Friday after it reported positive results of a Phase 2b study for breast cancer.

The study showed that patients treated with a combination of nelipepimut-S (NPS) and trastuzumab showed a 90.6% decrease in the risk of relapse or death at 24 months, especially for patients with the HLA-A24 allele, a human leukocyte antigen serotype common in Asians, the company said.

Shares of SELLAS shot up 31.5% to the day's high of $2.46 on the news, before sharply pruning their gains.

READ: SELLAS Life Sciences shares pop after presenting treatment on breast cancer

“These data not only confirm the clinical effect of the NPS plus trastuzumab combination ... but also positions NPS biologically as an agent that could potentially be used globally, considering the high prevalence of the HLA-A24 allele in populations across the Pacific basin and Asia," said Doctor Angelos Stergiou, president and CEO of SELLAS.

He said they will talk with US regulators in December 2018 on the best way for an "expeditious development path for NPS" and try to advance interaction with potential partners.SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company which focuses on the development of immunotherapies for various cancer indications.

The company is based in New York City.

Reporting by Rene Pastor, contactable on [email protected] 

Quick facts: SELLAS Life Sciences Group Inc

Price: $0.15

Market: NASDAQ
Market Cap: $34.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Musgrave Minerals intersects high-grade gold at Lena and Mainland Prospects

Musgrave Minerals Ltd (ASX:MGV) managing director Rob Waugh updates Proactive Investors on high-grade gold intersected from drilling at the company’s flagship Cue Gold Project in Western Australia.   Both results are below the current JORC resource and highlight the potential to extend...

14 hours, 23 minutes ago

RNS

Net Asset Value(s)

9 hours, 34 minutes ago

Net Asset Value(s)

1 day, 10 hours ago

Transaction in Own Shares

1 day, 13 hours ago

Net Asset Value(s)

4 days, 10 hours ago

Portfolio Valuation

5 days, 3 hours ago

Net Asset Value(s)

5 days, 10 hours ago

Net Asset Value(s)

6 days, 9 hours ago

Net Asset Value(s)

1 week, 1 day ago

2 min read